ncl1 Antibody

What is NCL1 and what is its primary mechanism of action?

NCL1 is a novel, highly selective inhibitor of lysine-specific demethylase 1 (LSD1). Its primary mechanism involves impairing LSD1 demethylase activity, which leads to the accumulation of histone H3 lysine 9 dimethylation (H3K9me2) at specific gene promoters. This epigenetic modification affects gene expression patterns critical for cancer cell survival and proliferation. Unlike less selective LSD1 inhibitors, NCL1 shows higher specificity in targeting cancer cells while having less effect on normal cells .

How does NCL1 compare to other LSD1 inhibitors such as PCPA (tranylcypromine)?

NCL1 demonstrates superior selectivity and efficacy compared to first-generation LSD1 inhibitors like PCPA. In experimental models, NCL1 induced significantly more TUNEL-positive cells (indicating apoptosis) compared to PCPA at equivalent doses. This suggests NCL1 has enhanced anti-tumor activity with potentially fewer off-target effects. Additionally, NCL1 appears to regulate both apoptotic and autophagic pathways, whereas earlier inhibitors primarily affected apoptosis .

What cancer types has NCL1 been studied in?

While NCL1 has shown potential across multiple cancer types, it has been most extensively studied in prostate cancer models, particularly in hormone-sensitive (LNCaP) and castration-resistant prostate cancer (CRPC) cell lines (22Rv1, PC3, PCai1, PCai1CS). Previous research has also indicated potential efficacy in glioma and breast cancer cell lines . Research continues to expand into additional cancer types where LSD1 overexpression plays a significant role.

How should NCL1 be administered in animal models?

In subcutaneous tumor models using castrated nude mice, NCL1 has been successfully administered via intraperitoneal injection at doses of 0.5-1.0 mg/kg. This dosage range has shown significant tumor growth inhibition without observable adverse effects on body weight, organ size, or blood parameters. Administration schedules typically involve regular injections throughout the experimental period, with tumor volume measurements performed at consistent intervals .

What control compounds and experimental controls should be used in NCL1 studies?

PCPA (tranylcypromine), a first-generation LSD1 inhibitor, serves as an effective positive control for comparing NCL1's selective inhibitory effects. Vehicle controls using the same solvent as NCL1 are essential for baseline comparisons. Additionally, siRNA knockdown of LSD1 provides a complementary approach to validate that observed effects are specifically due to LSD1 inhibition rather than off-target effects of the compound .

How does NCL1 affect gene expression in prostate cancer cells?

NCL1 specifically impairs the demethylation of H3K9me2 at androgen-response elements containing promoters, including the ETS domain-containing protein 4 (ELK4) and kallikrein 2 (KLK2) genes. ChIP analysis confirms the accumulation of H3K9me2 at these promoters following NCL1 treatment. This leads to reduced expression of androgen-responsive genes like ELK4 and KLK2, though interestingly, it does not affect androgen receptor (AR) expression or prostate-specific antigen (PSA) levels .

How does NCL1 regulate cell cycle progression in cancer cells?

NCL1 induces G0/G1 cell cycle arrest in prostate cancer cells through multiple mechanisms. Treatment results in decreased expression of cyclin D1 and reduced levels of cyclin-dependent kinases (CDK2 and CDK4). Simultaneously, NCL1 increases expression of cell cycle inhibitors p21WAF and p27KIP. Flow cytometry analysis confirms significant accumulation of cells in the G0/G1 phase following NCL1 treatment, demonstrating its ability to halt cell cycle progression in a dose-dependent manner .

What is the relationship between NCL1 treatment and autophagy?

NCL1 significantly induces autophagy in cancer cells, as evidenced by increased LC3-II protein levels in multiple prostate cancer cell lines. Transmission electron microscopy reveals the formation of autophagosomes within 3 hours of NCL1 treatment, with increased lysosomal structures appearing from 24-72 hours. LysoTracker analysis confirms the accumulation of activated lysosomes following NCL1 treatment. When combined with chloroquine (an autophagy inhibitor), NCL1's anti-cancer effects are enhanced synergistically, suggesting that NCL1-induced autophagy may serve as a protective mechanism that, when blocked, leads to increased cancer cell death .

What are the effects of NCL1 on castration-resistant prostate cancer (CRPC)?

NCL1 effectively inhibits CRPC cell growth both in vitro and in vivo. In CRPC cell lines (PC3, PCai1CS, 22Rv1), NCL1 demonstrates potent anti-proliferative effects despite these cells' resistance to conventional androgen deprivation therapy. Notably, LSD1 expression remains high in CRPC cells even after castration, making it a viable therapeutic target. Immunohistochemical analysis of human specimens shows consistently high LSD1 expression in CRPC tissues, including aggressive neuroendocrine differentiated phenotypes, suggesting NCL1 may be effective against advanced forms of prostate cancer .

What combination therapies show synergistic effects with NCL1?

The combination of NCL1 with chloroquine (CQ) demonstrates significant synergistic effects in prostate cancer cells. Combination index analysis confirms true synergy rather than merely additive effects. This combination enhances apoptotic cell death as measured by flow cytometry. The mechanistic basis appears to be that CQ inhibits autophagic flux (a potential survival mechanism), thereby enhancing NCL1's cytotoxic effects. This finding suggests autophagy inhibitors may be valuable adjunctive therapies when using LSD1 inhibitors like NCL1 .

What markers should be monitored to assess NCL1 efficacy in experimental models?

To comprehensively assess NCL1 efficacy, researchers should monitor:

• Epigenetic markers: H3K9me2 levels at target gene promoters via ChIP assay

• Cell cycle proteins: Cyclin D1, CDK2, CDK4, p21WAF, and p27KIP via Western blot

• Apoptosis markers: Cleaved caspase 3 and TUNEL assay positivity

• Autophagy indicators: LC3-I to LC3-II conversion, autophagosome formation via TEM

• Androgen-responsive genes: ELK4 and KLK2 expression levels

• Tumor angiogenesis: CD31-positive vessel density in tumor sections

• In vivo tumor metrics: Tumor volume, weight, and histological features

What assays are most effective for measuring NCL1's impact on histone methylation?

Chromatin immunoprecipitation (ChIP) assay is the gold standard for assessing NCL1's impact on histone methylation patterns. For NCL1 specifically, researchers should focus on H3K9me2 accumulation at androgen-responsive gene promoters. The methodology should include:

• Crosslinking with formaldehyde

• Chromatin fragmentation (typically via sonication)

• Immunoprecipitation with specific antibodies against H3K9me2

• PCR amplification of regions of interest (such as ELK4 and KLK2 promoters)

• Quantification relative to input chromatin and IgG controls

Western blotting for global H3K9me2 levels can provide complementary data but lacks the gene-specific resolution of ChIP analysis.

How should researchers quantify autophagy induction following NCL1 treatment?

A multi-pronged approach to autophagy assessment provides the most reliable results:

• Western blot analysis of LC3-II/LC3-I ratios with and without lysosomal inhibitors like chloroquine

• Transmission electron microscopy (TEM) to visualize autophagosomes and autolysosomes

• LysoTracker staining to quantify activated lysosomes

• Combination experiments with autophagy inhibitors (chloroquine) to assess autophagic flux

• Immunofluorescence for LC3 puncta formation

Calculating combination indices when using NCL1 with autophagy inhibitors can provide valuable information about the role of autophagy in the cellular response to LSD1 inhibition.

What parameters should be monitored in animal studies using NCL1?

The following table summarizes key parameters to monitor in animal studies using NCL1:

These parameters provide a comprehensive assessment of both efficacy and safety. Based on previous studies, NCL1 at 0.5-1.0 mg/kg does not significantly alter organ weights or blood chemistry parameters compared to control animals, suggesting a favorable safety profile at therapeutic doses .